Lexicon Pharmaceuticals Inc
lexpharma.comLexicon Pharmaceuticals (NASDAQ: LXRX) is a biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs targeting diseases with unmet medical need. Revenue comes from net product sales, licensing fees, and royalties tied to partnerships with larger pharmaceutical companies. The company's lead asset is sotagliflozin, an SGLT1/2 inhibitor approved in the United States. In October 2024, Lexicon granted Viatris Inc. an exclusive, royalty-bearing license to develop and commercialize sotagliflozin in an international territory, receiving a $25 million upfront payment with eligibility for up to $12 million in regulatory milestones, up to $185 million in sales milestones, and tiered royalties ranging from low double-digit to upper-teens percentages of annual net sales. The company continues to advance additional internal drug candidates, including LX9851 and pilavapadin, and reported third-party R&D services costs of $33.0 million in FY2025, down 42% from $56.7 million in FY2024. Lexicon operates at a net loss across all reported periods through FY2025.
Products & Services
Sotagliflozin: approved drug (heart failure indication) commercialized in the U.S. directly and licensed to Viatris Inc. for international markets including the UAE, with applications filed in Canada, Australia, and New Zealand as of the 10-K filed 2026-03-05. LX9851 and pilavapadin: pipeline drug candidates in clinical development. Lexicon also supplies sotagliflozin to Viatris under a manufacturing and supply agreement at an agreed transfer price.
Revenue Model
Three revenue streams: net product revenue from direct commercial sales, licensing revenue from upfront and milestone payments under partnership agreements, and royalties from licensee net sales. The Viatris agreement illustrates the model: $25 million upfront, milestone-contingent payments, and tiered royalties on international sotagliflozin sales.
Customers & Markets
End markets are cardiovascular disease (sotagliflozin for heart failure) and neuroscience (pilavapadin, originated from collaborative work with Bristol-Myers Squibb). Viatris Inc. is a material licensing and supply customer. Patients with heart failure represent the primary end-user population for sotagliflozin.
Geographic Exposure
United States: direct commercialization of sotagliflozin. International licensed territory: Viatris holds commercialization rights; sotagliflozin approved in the UAE as of the 10-K filed 2026-03-05, with regulatory applications pending in Canada, Australia, and New Zealand.
Financial Snapshot
Loading...
